Subject to final approval by the European Commission, the drug will be the first once-every-two-months long-acting injectable (LAI) antipsychotic licensed in the EU for adult patients with ...

European Medicines Agency Commences Review of Aripiprazole 2-Month Long-Acting Injectable for the Maintenance Treatment of Schizophrenia in Adult Patients Stabilised with Aripiprazole Otsuka ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved a new drug application for a treatment for schizophrenia or bipolar I disorder. The injectable ...